Levonadifloxacin (S-(-)-Nadifloxacin; WCK 771)|cas:154357-42-3|西域试剂

Levonadifloxacin (S-(-)-Nadifloxacin; WCK 771),99.79%

产品编号：Bellancom-14926| CAS NO：154357-42-3| 分子式：C₁₉H₂₁FN₂O₄| 分子量：360.38

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-14926	￥2500.00	杭州北京（现货）
Bellancom-14926	￥3800.00	杭州北京（现货）
Bellancom-14926	￥7500.00	杭州北京（现货）
Bellancom-14926	￥12000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Levonadifloxacin (S-(-)-Nadifloxacin; WCK 771)

产品介绍

Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) 是一种广谱的抗葡萄球菌剂。Levonadifloxacin 对甲氧西林敏感的金黄色葡萄球菌 (MSSA) 和对甲氧西林耐药的金黄色葡萄球菌具有抗菌活性，减少单核细胞 THP-1 吞噬的 MRSA 和 MSSA 菌株。

生物活性

Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) is a broad-spectrum anti-staphylococcal agent. Levonadifloxacin shows antibacterial activity against Methicillin (HY-121544)-susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, with a reduction of which phagocytized in THP-1 monocytes.

体外研究

Levonadifloxacin (32 μg/mL; 24 h) achieves a 90-99% intracellular reduction of MSSA and MRSA strains phagocytized in THP-1 monocytes with MICs of 0.03 μg/mL and 15.0 ng/mL.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Levonadifloxacin (12.5-400 mg/kg; s.c.; single dose) shows efficacy in vivo against Staphylococcus aureus in a Neutropenic Murine Lung Infection Model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male/Female Swiss Albino mice (25-28 g) for plasma pharmacokinetic analyses

Dosage:

12.5, 25, 50, 100, 200, 300 and 400 mg/kg

Administration:

Subcutaneous injection; single dose; collected samples at 10 time points/dose (0.25, 0.5, 1, 2, 4, 6, 8, 10, 58 12 and 24 h post dose)

Result:

Dose (mg/kg)	C_max (mg/L)	AUC_{0-24 h} (mg·h/L)	T_1/2 (h)
12.5	4.37	7.30	1.79
25	8.71	15.75	1.48
50	19.21	33.36	1.48
100	38.65	70.86	1.76
200	77.29	145.48	1.69
300	92.46	286.19	2.44
400	115.16	393.52	1.74

体内研究

Levonadifloxacin (12.5-400 mg/kg; s.c.; single dose) shows efficacy in vivo against Staphylococcus aureus in a Neutropenic Murine Lung Infection Model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male/Female Swiss Albino mice (25-28 g) for plasma pharmacokinetic analyses

Dosage:

12.5, 25, 50, 100, 200, 300 and 400 mg/kg

Administration:

Subcutaneous injection; single dose; collected samples at 10 time points/dose (0.25, 0.5, 1, 2, 4, 6, 8, 10, 58 12 and 24 h post dose)

Result:

Dose (mg/kg)	C_max (mg/L)	AUC_{0-24 h} (mg·h/L)	T_1/2 (h)
12.5	4.37	7.30	1.79
25	8.71	15.75	1.48
50	19.21	33.36	1.48
100	38.65	70.86	1.76
200	77.29	145.48	1.69
300	92.46	286.19	2.44
400	115.16	393.52	1.74

性状

Solid

溶解性数据

In Vitro:

DMSO : 125 mg/mL (346.86 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.7748 mL	13.8742 mL	27.7485 mL
5 mM	0.5550 mL	2.7748 mL	5.5497 mL
10 mM	0.2775 mL	1.3874 mL	2.7748 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式